Pure Global

First-in-human Dose Escalation and Expansion Study With the SIRPฮฑ-directed Monoclonal Antibody BYON4228 - Trial NCT05737628

Access comprehensive clinical trial information for NCT05737628 through Pure Global AI's free database. This Phase 1 trial is sponsored by Byondis B.V. and is currently Not yet recruiting. The study focuses on Lymphoma. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05737628
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov โ€ข NCT05737628
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
First-in-human Dose Escalation and Expansion Study With the SIRPฮฑ-directed Monoclonal Antibody BYON4228
First-in-human Dose Escalation and Expansion Study With the SIRPฮฑ-directed Monoclonal Antibody BYON4228 Alone and in Combination With Rituximab to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy in Patients With Relapsed/Refractory CD20 Positive B-cell Non-Hodgkin's Lymphoma (NHL)

Study Focus

Lymphoma

BYON4228 + Rituximab

Interventional

drug

Sponsor & Location

Byondis B.V.

Timeline & Enrollment

Phase 1

Apr 01, 2023

Dec 01, 2025

100 participants

Primary Outcome

Incidence of dose-limiting toxicities

Summary

This is the first-in-human study with BYON4228, a humanized monoclonal antibody (mAb)
 directed against SIRPฮฑ.

ICD-10 Classifications

Hodgkin lymphoma
Follicular lymphoma
Non-Hodgkin lymphoma, unspecified
Follicular lymphoma, unspecified
Hodgkin lymphoma, unspecified

Data Source

ClinicalTrials.gov

NCT05737628

Non-Device Trial